Wearable Disposable Electrotherapy

We design and validate a novel electrotherapy platform, without any electronic components, using printed abundant environmentally-benign materials. Whereas existing electrotherapy devices use an independent power source and electronics to generate and control stimulation currents, our design eliminates the need for these components, reducing manufacturing complexity and costs. Our novel platform relies only on scalable manufacturing and environmentally-benign common materials. The disposable single-use platform is activated simply by placement on the body. A prescribed electrotherapy discharge is regulated by a novel electrochemical architecture. Production is scalable by relying only on additive manufacturing and low-cost materials, and tailored to any application in a flexible package (as discreet as adhesive bandages). The single-dose nature of this platform is a categorical shift from existing approaches with durable equipment that require programming and assembly to disposable electrodes for each use. Our Wearable Disposable Electrotherapy technology can be distributed like pharmacotherapy, with indications spanning neuromodulation of brain disorders, aesthetics, wound healing, transcutaneous drug delivery, and bioelectronic medicine. ### Competing Interest Statement The City University of New York holds patents on brain stimulation or battery technology with MB, AC, MFR as inventor. MB has equity in Soterix Medical Inc. AC has equity in Urban Electric Power. MB consults, received grants, assigned inventions, and/or served on the SAB of SafeToddles, Boston Scientific, GlaxoSmithKline, Biovisics, Mecta, Lumenis, Halo Neuroscience, Google-X, i-Lumen, Humm, Allergan (Abbvie), Apple, Ybrain, Ceragem, Remz. MB is supported by grants from Harold Shames and the National Institutes of Health: NIH-NIDA UG3DA048502, NIH-NIGMS T34 GM137858, NIH-NINDS R01 NS112996, NIH-NINDS R01 NS101362, and NIH-G-RISE T32GM136499.